Vanzacaftor/tezacaftor/deutivacaftor
Orphan DrugFDA Approved (2024)
Description
A once-daily next-generation triple-combination CFTR modulator for cystic fibrosis in patients aged 6 years and older with at least one responsive CFTR mutation. FDA-approved December 2024.
Indications & Therapeutic Use
Cystic fibrosis
Linked Diseases:
Global Availability (1 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| Standard Marketing Authorization | — | — | Approved |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Vanzacaftor/tezacaftor/deutivacaftor
| Generic Name | vanzacaftor/tezacaftor/deutivacaftor |
| Brands | 1 brand available |
| Active Ingredient | vanzacaftor + tezacaftor + deutivacaftor |
| Drug Class | Cystic fibrosis |
| Manufacturer | Vertex Pharmaceuticals |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Reg. Status | FDA Approved (2024) |
| Countries | 1 countries |
Authority Signals
Last Verified7/24/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations2 Validated Nodes